HUP0301389A2 - Purinszármazékok - Google Patents

Purinszármazékok

Info

Publication number
HUP0301389A2
HUP0301389A2 HU0301389A HUP0301389A HUP0301389A2 HU P0301389 A2 HUP0301389 A2 HU P0301389A2 HU 0301389 A HU0301389 A HU 0301389A HU P0301389 A HUP0301389 A HU P0301389A HU P0301389 A2 HUP0301389 A2 HU P0301389A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
group
above compounds
alkyl group
alkylene
Prior art date
Application number
HU0301389A
Other languages
English (en)
Inventor
Simon John Mantell
Sandra Marina Monaghan
Peter Thomas Stephenson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0301389A2 publication Critical patent/HUP0301389A2/hu
Publication of HUP0301389A3 publication Critical patent/HUP0301389A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)

Abstract

Az (I) általános képletű vegyületek - a képletben R1 jelentése H,adott esetben szubsztituált 1-6 szénatomos alkilcsoport vagyfluorenilcsoport; R2 jelentése H vagy 1-6 szénatomos alkilcsoport; R3és R4 azzal a nitrogénatommal együtt, amelyhez kapcsolódnak, adottesetben szubsztituált azetidinil-, pirrolidinil-, piperidinil-,piperazinil-, homopiperidinil- vagy homopiperazinil-gyűrűt alkot, vagyR3 jelentése H, adott esetben szubsztituált 1-6 szénatomosalkilcsoport, 3-8 szénatomos cikloalkilcsoport vagy benzilcsoport; ésR4 jelentése adott esetben szubsztituált 1-6 szénatomos alkilcsoport,3-8 szénatomos cikloalkilcsoport, R15, -(2-6 szénatomos)alkilén-R8vagy -(1-6 szénatomos)alkilén-R13; R5 jelentése -CH2OH vagy -CONR14R14; X jelentése -CH2- vagy -CH2CH2-; és Y jelentése CO, CS, SO2vagy C=N(CN) és gyógyászatilag elfogadható sóik és szolvátjaikszelektív adenozin Aga receptor agonista aktivitásuk következtébengyulladásgátló szerként alkalmazhatók többek között légúti betegségekkezelésére. A találmány tárgyát képezi a fenti vegyületek előállítása,az előállításban alkalmazott köztitermékek, a fenti vegyületekettartalmazó gyógyászati készítmények, valamint a fenti vegyületekalkalmazása is. Ó
HU0301389A 2000-06-27 2001-06-14 Purine derivatives HUP0301389A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (en) 2000-06-27 2001-06-14 Purine derivatives

Publications (2)

Publication Number Publication Date
HUP0301389A2 true HUP0301389A2 (hu) 2003-08-28
HUP0301389A3 HUP0301389A3 (en) 2005-02-28

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301389A HUP0301389A3 (en) 2000-06-27 2001-06-14 Purine derivatives

Country Status (42)

Country Link
EP (1) EP1296996B1 (hu)
JP (1) JP2004501929A (hu)
KR (1) KR20030036248A (hu)
CN (1) CN1432020A (hu)
AP (1) AP1372A (hu)
AR (1) AR028759A1 (hu)
AT (1) ATE267836T1 (hu)
AU (1) AU2001264164A1 (hu)
BG (1) BG107171A (hu)
BR (1) BR0111912A (hu)
CA (1) CA2412564C (hu)
CZ (1) CZ20023992A3 (hu)
DE (1) DE60103537T2 (hu)
DK (1) DK1296996T3 (hu)
DO (1) DOP2001000195A (hu)
EA (1) EA200201291A1 (hu)
EC (1) ECSP024396A (hu)
EE (1) EE200200712A (hu)
ES (1) ES2220775T3 (hu)
GB (1) GB0015727D0 (hu)
GT (1) GT200100119A (hu)
HR (1) HRP20020995A2 (hu)
HU (1) HUP0301389A3 (hu)
IL (1) IL152529A0 (hu)
IS (1) IS6580A (hu)
MA (1) MA26918A1 (hu)
MX (1) MXPA03000078A (hu)
NO (1) NO20025975L (hu)
NZ (1) NZ521867A (hu)
OA (1) OA12294A (hu)
PA (1) PA8521001A1 (hu)
PE (1) PE20020213A1 (hu)
PL (1) PL361384A1 (hu)
PT (1) PT1296996E (hu)
SI (1) SI1296996T1 (hu)
SK (1) SK17332002A3 (hu)
SV (1) SV2002000507A (hu)
TN (1) TNSN01096A1 (hu)
TR (1) TR200401622T4 (hu)
UY (1) UY26797A1 (hu)
WO (1) WO2002000676A1 (hu)
ZA (1) ZA200209557B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
MX2007003271A (es) * 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Derivados de purina y metodos de uso de los mismos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0915173B8 (pt) 2008-06-11 2021-05-25 Agilent Technologies Inc compostos de nucleotídeos e nucleosídeos e método de sequenciamento de um ácido nucleico-alvo
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (hu) 2009-08-17 2015-08-21 Intellikine Llc
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
CA2317093A1 (en) * 1998-01-08 1999-07-15 Joel M. Linden A2a adenosine receptor agonists
ATE331726T1 (de) * 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
EA200201291A1 (ru) 2003-04-24
PT1296996E (pt) 2004-08-31
IS6580A (is) 2002-10-10
ZA200209557B (en) 2003-12-02
DE60103537T2 (de) 2005-07-07
ECSP024396A (es) 2003-02-06
SI1296996T1 (en) 2004-10-31
HUP0301389A3 (en) 2005-02-28
CA2412564A1 (en) 2002-01-03
CA2412564C (en) 2007-10-02
UY26797A1 (es) 2002-01-31
WO2002000676A1 (en) 2002-01-03
NZ521867A (en) 2004-04-30
JP2004501929A (ja) 2004-01-22
NO20025975D0 (no) 2002-12-12
ATE267836T1 (de) 2004-06-15
DOP2001000195A (es) 2002-05-15
TR200401622T4 (tr) 2004-08-23
TNSN01096A1 (fr) 2005-11-10
GT200100119A (es) 2002-01-31
PL361384A1 (en) 2004-10-04
HRP20020995A2 (en) 2005-02-28
PA8521001A1 (es) 2002-04-25
BG107171A (en) 2003-07-31
SV2002000507A (es) 2002-07-03
GB0015727D0 (en) 2000-08-16
DE60103537D1 (de) 2004-07-01
AR028759A1 (es) 2003-05-21
NO20025975L (no) 2002-12-12
EE200200712A (et) 2004-06-15
IL152529A0 (en) 2003-05-29
PE20020213A1 (es) 2002-03-19
MA26918A1 (fr) 2004-12-20
ES2220775T3 (es) 2004-12-16
AP1372A (en) 2005-02-21
CN1432020A (zh) 2003-07-23
EP1296996A1 (en) 2003-04-02
KR20030036248A (ko) 2003-05-09
MXPA03000078A (es) 2003-08-19
BR0111912A (pt) 2003-05-13
CZ20023992A3 (cs) 2003-12-17
AU2001264164A1 (en) 2002-01-08
DK1296996T3 (da) 2004-08-16
SK17332002A3 (sk) 2004-03-02
OA12294A (en) 2003-11-14
EP1296996B1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
HUP0301389A2 (hu) Purinszármazékok
HUP0001285A2 (hu) Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9903671A2 (hu) Gonadotropint leadó hormonok antagonistái,e vegyületeket tartalmazó gyógyászati készítmények,valamint azok előállítása
MXPA01004256A (es) N-arilamidas del acido antranilico y del acido tioantranilico.
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0102851A2 (hu) Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0204029A2 (hu) Trifenilalkilén-származékok és szelektív ösztrogén receptor modulátorokként történő alkalmazásuk
HUP0204245A2 (hu) Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401950A2 (hu) Pirimidin-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
HUP0002031A2 (hu) Benzotiofénszármazékok alkalmazása központi idegrendszeri betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0300148A2 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
HUP0300527A2 (hu) Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása
HUP0204246A2 (hu) Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
HUP0203836A2 (hu) 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
AP2001002302A0 (en) 13-Methyl erythromycin derivatives.
TW200616636A (en) Novel compounds
MY114548A (en) New arylglycineamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
NO304379B1 (no) 11,21-bisfenyl-19-norpregnan-derivater, anvendelse derav og farmas°ytiske preparater inneholdende slike derivater